Minoxidil and Its Use in Hair Disorders: A Review [Corrigendum]

Abstract

Suchonwanit P, Thammarucha S, Leerunyakul K. Drug Des Devel Ther. 2019;13:2777–2786. On page 2781, Androgenetic alopecia section, last paragraph, “A combination of low-dose minoxidil 2.5 mg and spironolactone 25 mg in patients with FPHL showed preferable outcomes with decrease hair shedding and improved hair density. The mean severity score reduced to 2.3 at 6 months and 2.6 at 12 months. Mild adverse effects including urticaria, postural hypotension, and facial hypertrichosis were reported.” should read “A combination of low-dose minoxidil 0.25 mg and spironolactone 25 mg in patients with FPHL showed preferable outcomes with decrease hair shedding and improved hair density. Mean reduction in hair shedding score was 2.3 at 6 months and 2.6 at 12 months. Mild adverse effects including urticaria, postural hypotension, and facial hypertrichosis were reported.” Following feedback from a reader, we found 1) the incorrect dosage was listed for minoxidil and 2) the reduction in severity score relates to the visual-analogue Sinclair hair shedding scale. The authors apologize for these errors.